"Bioresorbable Scaffolds: Where Do We Go From Here?" - L.A. McKeown
Will they or won't they? That's the question many are asking about whether bioresorbable scaffolds (BRS) will evolve from their current state of flux to commonplace tools in the interventional cardiology world. In a spirited debate at the (SCAI) 2017 Scientific Sessions last week, the overall message was one of optimism tinged with caution. Roxana Mehran, MD, a professor of cardiology at the Icahn School of Medicine at Mount Sinai, noted that what started as a "green light" for the technology quickly changed as troubling real-world data emerged. "We are really in a kind of quandary and a cautionary place right now with so many meta-analyses showing higher scaffold thrombosis - both from the ABSORB II 3-year data, and most recently from the AIDA trial," said Dr. Mehran.
- Roxana Mehran, MD, Professor, Medicine, Cardiology, Population Science and Health Policy, Director, Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai
Coronary Stent Patients May Not Need Long-Term Aspirin
Sep 26, 2019 View All Press Releases